• Home Dutch
  •  EN 
  • Employee login

Pharmacogenetics and response to treatment of oral antidiabetics

Print 
Title:  Pharmacogenetics and response to treatment of oral antidiabetics
Investigator(s):  Doti Martono
Supervisor(s):  Bob Wilffert
Promotores:  Bob Wilffert, Eelko Hak, Petra Denig, Hiddo Lambers-Heerspink
Summary:   Metformin is the first line therapy in type 2 diabetes mellitus, followed by sulfonylurea compounds as a second step or alternative. Variability of response to treatment in type 2 diabetic patients, which may be caused by clinical or genetic factors, has been elaborated in previous studies but not clearly understood. The understanding of these determining factors may serve as a guide to make better drug choices at the start of treatment. The aim of this study is to analyze the demographic, clinical, and genetic characteristics of patients with type 2 diabetes in relation to drug treatment. The association of these characteristics with treatment response will further be examined. Using the GIANTT cohort with additional data collection, we plan to determine: (1) characteristics of new users of oral antidiabetics starting on metformin and starting on sulfonylurea derivatives (SU derivatives), (2) demographic and clinical predictors of HbA1c treatment response in patients starting on metformin or SU derivatives, (3) genetic predictors of HbA1c treatment response in patients starting on metformin or SU derivatives, focusing on both risk alleles and pathway-related genetic polymorphisms, with adjustments for demographic and clinical predictors.
Financing:  1e GS, University of Groningen
Start:  1-9-2012
End: 1-9-2016

 

Projects
The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects